5414x May 2026

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update

The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights: : Established a strategic collaboration with Cepheid (a

: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion . supported by synthetic biology.

: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas. : Established a strategic collaboration with Cepheid (a

: £13.0 million (+52.9%), driven by AMR and EMEAI growth.

: £12.9 million (+27.4%), supported by synthetic biology.